Newsroom | 23681 results

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient- centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and affirmed its 2025 guidance. “Our business model remains fundamentally strong as we continue to deliver member and top-line growth, quality outcomes, and provider retention,” said Aric Coffman, CEO of P3. “With the $130M+...

DUBLIN--(BUSINESS WIRE)--The "Pediatric Interventional Cardiology Market Report by Device Type, Procedure, End Use, Country and Company Analysis 2025 to 2033" report has been added to ResearchAndMarkets.com's offering. The Pediatric Interventional Cardiology market is poised for substantial growth, with projections estimating an increase from US$ 2.42 billion in 2024 to US$ 4.34 billion by 2033. This remarkable growth, registering a CAGR of 6.68% from 2025 to 2033, is driven by advancements in...

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2025 payable on May 15, 2025 to all shareholders of record as of April 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled soluti...

RIVERSIDE, Calif.--(BUSINESS WIRE)--Manifest MedEx (MX), California’s largest nonprofit health data network and CalHHS Data Exchange Framework (DxF) Qualified Health Information Organization (QHIO), today announced the addition of three new senior regional leaders: Eva Williams, PhD, Executive Director of the Southern Inland Region; Dr. Ednann Naz, Executive Director of the Central & Northern Regions; and Erin Henke, Executive Director of the Bay Region. “We are committed to making health d...

AACHEN, Alemania--(BUSINESS WIRE)--Protembis, empresa privada emergente dedicada a dispositivos médicos cardiovasculares, ha anunciado hoy la creación de un Consejo Científico Asesor (SAB) que proporcionará asesoramiento objetivo y contribuirá a los planes estratégicos de la empresa. En concreto, el CCC aportará orientación estratégica científica y clínica, asesorará sobre y oportunidades emergentes y tendencias, y proporcionará asesoramiento experto sobre asuntos científicos y clínicos. El Con...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Embold Health uses conversational AI to guide members to the right provider, lowering costs and improving health outcomes....

雪梨--(BUSINESS WIRE)--(美國商業資訊)-- 國際知名的全方位受託研究機構 (CRO) 及科學諮詢公司Novotech發佈新的臨床前研究報告，深入探討小分子干擾RNA (siRNA) 治療領域的發展態勢。本報告透過深度洞察，旨在幫助生物技術與製藥企業運用RNA精準醫學技術，開拓新一代腫瘤學、代謝疾病及罕見遺傳疾病治療方案的新篇章。 挖掘siRNA在藥物研發中的潛力 siRNA療法透過精準沉默致病基因，為標靶藥物開發帶來了典範轉移。美國食品藥物管理局 (FDA) 核准了包括ONPATTRO™ (Patisiran) 和Inclisiran在內的多款siRNA藥物，該領域在遞送平台、穩定性及組織特異性標靶方面取得了快速進展。Novotech的報告概述當前的研發態勢與監管環境，並著重闡述siRNA技術如何擴展可成藥基因組，突破昔日的難成藥標靶問題。 主要重點： 臨床與監管情況：概述六種已獲FDA核准的siRNA療法，及其在心血管、肝臟及罕見遺傳疾病領域的適應症擴展情況。 siRNA遞送技術的進展：探討脂質奈米粒子 (LNPs)、GalNAc複合體和聚合物奈米粒子等創新突破，...

悉尼--(BUSINESS WIRE)--(美国商业资讯)-- 国际知名的全方位临床研究组织（CRO）及科学咨询公司Novotech（诺为泰）发布新的临床前研究报告，深入探讨了小干扰RNA (siRNA) 治疗领域的发展态势。本报告通过深度洞察，旨在帮助生物技术与制药企业依托RNA精准医学技术，开拓新一代肿瘤学、代谢疾病及罕见遗传病治疗方案的新篇章。 挖掘siRNA在药物研发中的潜力 siRNA疗法通过精准沉默致病基因，为靶向药物开发带来了范式转变。美国食品药品监督管理局 (FDA) 批准了包括ONPATTRO™（帕蒂西兰）和英克司兰在内的多款siRNA药物，该领域在递送平台、稳定性及组织特异性靶向方面取得了快速进展。诺为泰的报告梳理了当前的研发态势与监管环境，并着重阐述了了siRNA技术如何扩展可成药基因组，突破昔日的难成药靶点问题。 主要亮点： 临床与监管情况：概述了六种已获FDA批准的siRNA疗法，及其在心血管、肝脏及罕见遗传病领域的适应症扩展情况。 siRNA递送技术的进展：探讨了脂质纳米颗粒 (LNPs)、GalNAc偶联物和聚合物纳米颗粒等创新突破，如何提升组织靶向递送效...

SYDNEY--(BUSINESS WIRE)--Novotech, a top global clinical trial provider, partners with biotech and pharma to speed siRNA therapeutic development....

CHARLESTOWN, Mass.--(BUSINESS WIRE)--Hallmark partners with CareRev to give hospitals instant access to 35K+ per diem nurses, boosting flexibility and cutting staffing costs....